manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa

83. Jonas MM, Mizierski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al .
Clinical trial of lamivudine in children with chronic hepatitis B. NEJM, 2002;
346:1706-13
84. Lebensztejn DM, Skiba E, Sobieniec-Lotowska M, Kaczmarski M. The
HBe/antiHBe seroconversion as a result of lamivudine treatment in children with
chronic hepatitis B unresponsive to previous interferon alfa therapy. Pol
Merkuriusz Lek 2004;16:557-9
85. Ertekin V., Selimoğlu M. A.,Orbak. Et al, Effects of lamivudine therapy on the
glucose metabolism in children with chronic hepatitis B: first year follow-up
results. Eur Jour of Gastroenterol & Hepatol(2005)
86. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al .
Predictors of HBeAg loss Lamivudine treatment for chronic hepatitis B.
Hepatology 2002;36:186-94
87. Niesters HG, de Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new
variant in the YMDD motif of the hepatitis B virus polymerase gene selected
during lamivudine therapy. J Med Microbiol 2002;51:695-9
88. Hadziyannis SJ, Vassilopoulos D. Complex management issues: management of
HCV in the atypical patient. Baillière's Clin Gastroenterol 2000;1 4:277–91
89. Jara;P.,Hierro L., Treatment of Hepatitis C in children, Expert Rev Gastroenterol
Hepatol. 2010;4(1):51-61
90. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for
chronic hepatitis C virus infection. NEJM; 2002;347:975–82
91. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients
with chronic hepatitis C and cirrhosis. NEJM 2000;343:1673–80
92. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with
chronic hepatitis C. NEJM, 2000;343:1666–72
93. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a
remission of autoimmune hepatitis in children. J Hepatol. Feb 1999;30(2):222-7
94. Sciveres M, Caprai S, Palla G, et al. Effectiveness and safety of ciclosporin as
therapy for autoimmune diseasesof the liver in children and adolescents. Aliment
Pharmacol Ther. Jan 15 2004;19(2):209-17
95. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate
mofetil as rescue treatment for autoimmune liver disease in children: a 5-year
follow-up. J Hepatol. Jul 2009;51(1):156-60
96. Peek S.F. et al, Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methylβ,
L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and
gene expression in chronically infected woodchucks (Marmota monax), Hepatol,
Ian 2001, 33( 1) :254-266
97. van Bömmel F. et al, Tenofovir for patients with lamivudine-resistant hepatitis B
virus (HBV) infection and high HBV DNA level during adefovir therapy, Mar
2006, Hepatol, 44 (2) :318-325
98. Ka Lau G., et al, Combination therapy with lamivudine and famciclovir for
chronic hepatitis B–infected Chinese patients: A viral dynamics study, Hepatol,
Aug. 2000, 32(2):394-399